ANP32D Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA5103290-Each-of-1 | In Stock | ₹ 46,502.50 |
PIPA5103290 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 46,502.50
GST (18%): ₹ 8,370.45
Total Price: ₹ 54,872.95
Antigen
ANP32D
Classification
Polyclonal
Conjugate
Unconjugated
Gene
ANP32D
Gene Alias
acidic (leucine-rich) nuclear phosphoprotein 32 family, member D; acidic leucine-rich nuclear phosphoprotein 32 family member D; acidic nuclear phosphoprotein 32 family member D; acidic nuclear phosphoprotein 32D; ANP32D; Phosphoprotein 32-related protein 2; pp32 related 2; PP32R2; Tumorigenic protein pp32r2
Host Species
Rabbit
Purification Method
Affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
23519
Content And Storage
-20°C
Form
Liquid
Applications
Western Blot
Concentration
1 mg/mL
Formulation
PBS with 50% glycerol and 0.02% sodium azide; pH 7.4
Gene Accession No.
O95626
Gene Symbols
ANP32D
Immunogen
A synthesized peptide derived from human ANP32D(Accession O95626), corresponding to amino acid residues M1-E40.
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human
Product Type
Antibody
Isotype
IgG
Related Products
Description
- Antibody detects endogenous levels of total ANP32D
- ANP32D (acidic (leucine-rich) nuclear phosphoprotein 32 family, member D), also known as PP32R2 (phosphoprotein 32-related protein 2) or tumorigenic protein pp32r2, is a 131 amino acid protein that contains 3 leucine-rich repeats and belongs to the ANP32 family
- ANP32D shares 89.3% amino acid sequence identity with ANP32A, a tumor suppressor that inhibits a variety of cancers, such as prostate and breast cancers
- Although similar to ANP32A, ANP32D is tumorigenic and is preferentially expressed in prostatic cancer
- Conversely, it is uncertain that ANP32D is neurally expressed
- Intronless, ANP32D may be a pseudogene that is expressed in pathological situations and may also modulate the oncogenic potential of human prostate cancer.